The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies
Colorectal cancer (CRC) remains a significant cause of cancer-related mortality worldwide. Despite advancements in surgery, chemotherapy, and radiotherapy, the effectiveness of these conventional treatments is limited, particularly in advanced cases. Therefore, transition to novel treatment is urgen...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1440830/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841540155426471936 |
|---|---|
| author | Qingzhe Wang Min Yu Shuang Zhang |
| author_facet | Qingzhe Wang Min Yu Shuang Zhang |
| author_sort | Qingzhe Wang |
| collection | DOAJ |
| description | Colorectal cancer (CRC) remains a significant cause of cancer-related mortality worldwide. Despite advancements in surgery, chemotherapy, and radiotherapy, the effectiveness of these conventional treatments is limited, particularly in advanced cases. Therefore, transition to novel treatment is urgently needed. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has shown promise in improving outcomes for CRC patients. Notably, patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) tumors often benefit from ICIs, while the majority of CRC cases, which exhibit proficient mismatch repair (pMMR) or microsatellite-stable (MSS) status, generally show resistance to this approach. It is assumed that the MSI phenotype cause some changes in the tumor microenvironment (TME), thus triggering antitumor immunity and leading to response to immunotherapy. Understanding these differences in the TME relative to MSI status is essential for developing more effective therapeutic strategies. This review provides an overview of the TME components in CRC and explores current approaches aimed at enhancing ICI efficacy in MSS CRC. |
| format | Article |
| id | doaj-art-dbf2932a2dc340be852fbf31ef6d5195 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-dbf2932a2dc340be852fbf31ef6d51952025-01-14T06:10:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14408301440830The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategiesQingzhe Wang0Min Yu1Shuang Zhang2Department of Targeting Therapy and Immunology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Targeting Therapy and Immunology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaColorectal cancer (CRC) remains a significant cause of cancer-related mortality worldwide. Despite advancements in surgery, chemotherapy, and radiotherapy, the effectiveness of these conventional treatments is limited, particularly in advanced cases. Therefore, transition to novel treatment is urgently needed. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has shown promise in improving outcomes for CRC patients. Notably, patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) tumors often benefit from ICIs, while the majority of CRC cases, which exhibit proficient mismatch repair (pMMR) or microsatellite-stable (MSS) status, generally show resistance to this approach. It is assumed that the MSI phenotype cause some changes in the tumor microenvironment (TME), thus triggering antitumor immunity and leading to response to immunotherapy. Understanding these differences in the TME relative to MSI status is essential for developing more effective therapeutic strategies. This review provides an overview of the TME components in CRC and explores current approaches aimed at enhancing ICI efficacy in MSS CRC.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1440830/fullcolorectal cancertumor microenvironmentimmune checkpoint inhibitorsdeficient mismatch repairproficient mismatch repairmicrosatellite instable |
| spellingShingle | Qingzhe Wang Min Yu Shuang Zhang The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies Frontiers in Immunology colorectal cancer tumor microenvironment immune checkpoint inhibitors deficient mismatch repair proficient mismatch repair microsatellite instable |
| title | The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies |
| title_full | The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies |
| title_fullStr | The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies |
| title_full_unstemmed | The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies |
| title_short | The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies |
| title_sort | characteristics of the tumor immune microenvironment in colorectal cancer with different msi status and current therapeutic strategies |
| topic | colorectal cancer tumor microenvironment immune checkpoint inhibitors deficient mismatch repair proficient mismatch repair microsatellite instable |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1440830/full |
| work_keys_str_mv | AT qingzhewang thecharacteristicsofthetumorimmunemicroenvironmentincolorectalcancerwithdifferentmsistatusandcurrenttherapeuticstrategies AT minyu thecharacteristicsofthetumorimmunemicroenvironmentincolorectalcancerwithdifferentmsistatusandcurrenttherapeuticstrategies AT shuangzhang thecharacteristicsofthetumorimmunemicroenvironmentincolorectalcancerwithdifferentmsistatusandcurrenttherapeuticstrategies AT qingzhewang characteristicsofthetumorimmunemicroenvironmentincolorectalcancerwithdifferentmsistatusandcurrenttherapeuticstrategies AT minyu characteristicsofthetumorimmunemicroenvironmentincolorectalcancerwithdifferentmsistatusandcurrenttherapeuticstrategies AT shuangzhang characteristicsofthetumorimmunemicroenvironmentincolorectalcancerwithdifferentmsistatusandcurrenttherapeuticstrategies |